Abstract
purpose. To test the hypothesis that the structure and function of an experimental human choroidal melanoma xenograft and neighboring non–tumor-bearing retina can be simultaneously assessed by using manganese-enhanced MRI (MEMRI).
methods. Spheroids grown from the human choroidal melanoma cell line C918 were implanted in the superior suprachoroidal space of 11 WAG/Nij-rnu nude rats. Two weeks later, MRI data were collected 4 hours after intraperitoneal injection of saline or MnCl2, an MRI contrast agent that can act as a biomarker of cellular demand for ions, such as calcium. The following parameters were measured: (1) tumor signal intensity, (2) inner and outer retinal signal intensity in non–tumor-bearing inferior retina, and (3) whole and inner retinal thickness of inferior retina. Separate MEMRI experiments were performed on spheroids in vitro after MnCl2 exposure and washing.
results. In vitro, spheroids exposed to MnCl2 retained sufficient Mn2+ to demonstrate contrast enhancement during MEMRI. In vivo, injection of MnCl2 resulted in a 30% increase in tumor signal intensity compared with tumors in rats injected with saline (P < 0.05). In inferior retina of tumor-bearing eyes, outer retinal signal intensity increased by 17% relative to a similar region in control eyes (P < 0.05), but there was no change in the inferior inner retinal intensity. Total retinal thickness of the inferior retina in the tumor-bearing eyes increased by 8%, compared with that in the non–tumor-bearing eyes (P < 0.05).
conclusions. The present identification of regions of enhanced Mn2+ uptake in choroidal melanoma and a somewhat unexpected edema and increased outer retinal ion demand in neighboring non–tumor-bearing retina highlights MEMRI as a potentially powerful method for noninvasively monitoring tumor progression and treatment response and efficacy.
Uveal melanoma is the most common intraocular malignancy in adults, accounting for 70% of all primary eye cancers.
1 Although eye-sparing therapies such as radiation are equivalent to enucleation in terms of long-term survival,
2 these treatments do not always succeed in saving the patient’s vision.
3 Three to 5 years after plaque radiotherapy or proton beam therapy, only approximately 60% of all patients maintain a visual acuity better than 20/200.
4 5 6 Complications after proton beam therapy include radiation retinopathy,
7 papillopathy,
7 and cataract.
8 Given the incidence of ocular complications during treatment of choroidal melanoma, existing therapies must be optimized and new, more tumor-specific treatments should be developed. To achieve this goal, methods are needed for simultaneous determination of the effects of treatments on tumor growth and on the structure and function of the neighboring non–tumor-bearing retina.
Recent studies in the retina and brain have made use of Mn
2+ as an ion surrogate and a strong MRI contrast agent for functional manganese-enhanced MRI (MEMRI).
9 10 11 In the retina experiments, MnCl
2 was administered under different lighting conditions while the animal was outside the magnet. The resultant accumulation of Mn
2+ ions in nonvascular retina was detected noninvasively as an enhancement in T
1-weighted MRI images.
9 Similarly, in brain experiments, administration of MnCl
2 during a functional task resulted in the accumulation of Mn
2+ ions in activated brain structures and enhanced T
1-weighted MRI images.
10 11 These results indicate that accumulation of Mn
2+ and the resultant MRI intensity enhancement are function dependent. Free Mn
2+ ion has not yet been used to image tumors, although there is evidence that some tumors preferentially accumulate Mn
2+.
12 Based on these findings, we decided to test whether high-resolution MEMRI could be used to enhance the imaging of experimental human choroidal melanomas in the eyes of nude, athymic rats. In addition, because MEMRI has recently been used to determine retinal thickness and functional changes in ion demand in the inner and outer layers of the rat retina,
9 we also tested the hypothesis that structural and functional (i.e., ion demand) parameters of neighboring retina can be simultaneously monitored.
For the first time, systemic injection of a MnCl2 solution has been used to image a tumor by using MEMRI. The imaging of a human choroidal melanoma xenograft transplanted into the eye of a nude rat permitted the simultaneous evaluation of the tumor and the neighboring retina in the same eye. Mn2+ was taken up by the tumor, which resulted in contrast enhancement during MEMRI imaging. The retina in the inferior portion of the eye, which was not in direct contact with the tumor, was adversely affected by the presence of the melanoma. Inferior outer retinal MEMRI intensity was altered in those eyes, and the inferior retina was edematous. The use of the MEMRI technique in this choroidal melanoma model will permit the study of the impact of tumor growth on the neighboring retina and will allow the simultaneous evaluation of treatment-related side effects in the same eye.
The practical applicability of this method in humans has not yet been evaluated. However, we note that a manganese-based contrast agent (Mangafodipir Trisodium [Teslascan]; GE Healthcare, Princeton, NJ) already has FDA approval and that motion–artifact free high-resolution MRIs of the human retina can be routinely collected.
27 28 29 30 These considerations raise the possibility of clinically monitoring choroidal melanoma progression and/or treatment response using MEMRI in patients.
Supported by National Eye Institute Grants R03EY016795 (RDB) and R01EY013831 (BAB) and National Eye Institute Departmental Core Grant P30EY04068.
Submitted for publication September 26, 2006; revised November 13, 2006; accepted January 15, 2007.
Disclosure:
R.D. Braun, None;
M. Gradianu, None;
K.S. Vistisen, None;
R.L. Roberts, None;
B.A. Berkowitz, None
The publication costs of this article were defrayed in part by page charge payment. This article must therefore be marked “
advertisement” in accordance with 18 U.S.C. §1734 solely to indicate this fact.
Corresponding author: Rod D. Braun, Anatomy and Cell Biology, Wayne State Univ School of Medicine, 540 E. Canfield Avenue, Detroit, MI 48201;
rbraun@med.wayne.edu.
Table 1. Average Signal Intensity of Tumor after Saline or MnCl2 Injection
Table 1. Average Signal Intensity of Tumor after Saline or MnCl2 Injection
Injection | In-Plane Tumor Area (mm2) | Average Signal Intensity (AU) | Number of Rats |
Saline | 2.25 ± 0.76 | 114.1 ± 13.1 | 5 |
MnCl2 | 3.89 ± 2.33 | 148.9 ± 25.5 | 6 |
P * | 0.537 | 0.030 | |
Table 2. Average Retinal Thickness and Average Signal Intensity of the Inferior Retina in the Control Left Eye and the Tumor-Bearing Right Eye after MnCl2 Injection
Table 2. Average Retinal Thickness and Average Signal Intensity of the Inferior Retina in the Control Left Eye and the Tumor-Bearing Right Eye after MnCl2 Injection
Eye | Total Inferior Retinal Thickness (μm) | Inner Inferior Retinal Thickness (μm) | Inner Retinal Intensity (AU) | Outer Retinal Intensity (AU) | Rats (n) | P Inner vs. Outer Intensity |
Control | 228.6 ± 6.9 | 107.7 ± 3.2 | 181.0 ± 11.5 | 157.5 ± 15.4 | 6 | 0.031 |
Tumor-bearing | 246.1 ± 21.8 | 118.6 ± 15.4 | 178.5 ± 7.3 | 182.7 ± 9.3 | 6 | 0.438 |
Rats (n) | 6 | 5 | 6 | 6 | | |
P * | 0.031 | 0.188 | 0.563 | 0.031 | | |
The authors thank Mary Hendrix and Karla Daniels for kindly supplying the C918 cells.
SahelJA, AlbertDM. Intraocular melanomas. Cancer Treat Res. 1993;65:161–199.
[PubMed]Diener-WestM, EarleJD, FineSL, et al. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, III: initial mortality findings. COMS Report No. 18. Arch Ophthalmol. 2001;119:969–982.
[CrossRef] [PubMed]FingerPT. Radiation therapy for choroidal melanoma. Surv Ophthalmol. 1997;42:215–232.
[CrossRef] [PubMed]COMS. Collaborative ocular melanoma study (COMS) randomized trial of I-125 brachytherapy for medium choroidal melanoma: I. visual acuity after 3 years COMS report no. 16. Ophthalmology. 2001;108:348–366.
[CrossRef] [PubMed]ShieldsCL, ShieldsJA, CaterJ, et al. Plaque radiotherapy for uveal melanoma: long-term visual outcome in 1106 consecutive patients. Arch Ophthalmol. 2000;118:1219–1228.
[CrossRef] [PubMed]GragoudasES, LaneAM, ReganS, et al. A randomized controlled trial of varying radiation doses in the treatment of choroidal melanoma. Arch Ophthalmol. 2000;118:773–778.
[CrossRef] [PubMed]GragoudasES, LiW, LaneAM, MunzenriderJ, EganKM. Risk factors for radiation maculopathy and papillopathy after intraocular irradiation. Ophthalmology. 1999;106:1571–1578.
[CrossRef] [PubMed]GragoudasES, EganKM, WalshSM, ReganS, MunzenriderJE, TaratutaV. Lens changes after proton beam irradiation for uveal melanoma. Am J Ophthalmol. 1995;119:157–164.
[CrossRef] [PubMed]BerkowitzBA, RobertsR, GoebelDJ, LuanH. Noninvasive and simultaneous imaging of layer-specific retinal functional adaptation by manganese-enhanced MRI. Invest Ophthalmol Vis Sci. 2006;47:2668–2674.
[CrossRef] [PubMed]LinYJ, KoretskyAP. Manganese ion enhances T
1-weighted MRI during brain activation: an approach to direct imaging of brain function. Magn Reson Med. 1997;38:378–388.
[CrossRef] [PubMed]YuX, WadghiriYZ, SanesDH, TurnbullDH. In vivo auditory brain mapping in mice with Mn-enhanced MRI. Nat Neurosci. 2005;8:961–968.
[CrossRef] [PubMed]TamanoH, EnomotoS, OkuN, TakedaA. Preferential uptake of zinc, manganese, and rubidium in rat brain tumor. Nucl Med Biol. 2002;29:505–508.
[CrossRef] [PubMed]BraunRD, AbbasA. Orthotopic human choroidal melanoma xenografts in nude rats with aggressive and nonaggressive PAS staining patterns. Invest Ophthalmol Vis Sci. 2006;47:7–16.
[CrossRef] [PubMed]DanielsKJ, BoldtHC, MartinJA, GardnerLM, MeyerM, FolbergR. Expression of type VI collagen in uveal melanoma: its role in pattern formation and tumor progression. Lab Invest. 1996;75:55–66.
[PubMed]YuhasJM, LiAP, MartinezAO, LadmanAJ. A simplified method for production and growth of multicellular tumor spheroids. Cancer Res. 1977;37:3639–3643.
[PubMed]BerkowitzBA, ItoY, KernTS, McDonaldC, HawkinsR. Correction of early subnormal superior hemiretinal ΔPO
2 predicts therapeutic efficacy in experimental diabetic retinopathy. Invest Ophthalmol Vis Sci. 2001;42:2964–2969.
[PubMed]SchuppDG, MerkleH, EllermannJM, KeY, GarwoodM. Localized detection of glioma glycolysis using edited 1H MRS. Magn Reson Med. 1993;30:18–27.
[CrossRef] [PubMed]BerkowitzBA, KowluruRA, FrankRN, KernTS, HohmanTC, PrakashM. Subnormal retinal oxygenation response precedes diabetic-like retinopathy. Invest Ophthalmol Vis Sci. 1999;40:2100–2105.
[PubMed]AokiI, TakahashiY, ChuangKH, et al. Cell labeling for magnetic resonance imaging with the T
1 agent manganese chloride. NMR Biomed. 2006;19:50–59.
[CrossRef] [PubMed]GimiB, LeoniL, OberholzerJ, et al. Functional MR microimaging of pancreatic beta-cell activation. Cell Transplant. 2006;15:195–203.
[CrossRef] [PubMed]PeysterRG, AugsburgerJJ, ShieldsJA, HersheyBL, EagleR, Jr, HaskinME. Intraocular tumors: evaluation with MR imaging. Radiology. 1988;168:773–779.
[CrossRef] [PubMed]DryseliusS, GrapengiesserE, HellmanB, GylfeE. Voltage-dependent entry and generation of slow Ca
2+ oscillations in glucose-stimulated pancreatic beta-cells. Am J Physiol. 1999;276:E512–E518.
[PubMed]CrossgroveJS, YokelRA. Manganese distribution across the blood-brain barrier. IV. Evidence for brain influx through store-operated calcium channels. Neurotoxicology. 2005;26:297–307.
[CrossRef] [PubMed]LipskaiaL, LompreAM. Alteration in temporal kinetics of Ca
2+ signaling and control of growth and proliferation. Biol Cell. 2004;96:55–68.
[CrossRef] [PubMed]MunaronL, AntoniottiS, LovisoloD. Intracellular calcium signals and control of cell proliferation: how many mechanisms?. J Cell Mol Med. 2004;8:161–168.
[CrossRef] [PubMed]KohnEC, AlessandroR, SpoonsterJ, WerstoRP, LiottaLA. Angiogenesis: role of calcium-mediated signal transduction. Proc Natl Acad Sci USA. 1995;92:1307–1311.
[CrossRef] [PubMed]AdamG, BrabM, BohndorfK, GuntherRW. Gadolinium-DTPA-enhanced MRI of intraocular tumors. Magn Reson Imaging. 1990;8:683–689.
[CrossRef] [PubMed]BerkowitzBA, McDonaldC, ItoY, ToftsPS, LatifZ, GrossJ. Measuring the human retinal oxygenation response to a hyperoxic challenge using MRI: eliminating blinking artifacts and demonstrating proof of concept. Magn Reson Med. 2001;46:412–416.
[CrossRef] [PubMed]TrickGL, EdwardsP, DesaiU, BerkowitzBA. Early supernormal retinal oxygenation response in patients with diabetes. Invest Ophthalmol Vis Sci. 2006;47:1612–1619.
[CrossRef] [PubMed]TrickGL, LiggettJ, LevyJ, et al. Dynamic contrast enhanced MRI in patients with diabetic macular edema: initial results. Exp Eye Res. 2005;81:97–102.
[CrossRef] [PubMed]